2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

2330 Targeting an IFN-β-driven senescent macrophages to prevent acute-to-chronic transition of graft-versus-host disease

Xiaodong Xie Jr, PhD, Fengjuan Tian2, Yixiao Kang3, Rui Wang, MD4, Qingxiao Song, MD, PhD5, Xi Zhang, MD6
1 Xinqiao Hospital of Army Medical University, Chongqing, China
2 Xinqiao Hospital of Army Medical University, Chongqing, China
3 Xinqiao Hospital of Army Medical University, Chongqing, China
4 Xinqiao Hospital of Army Medical University, Chongqing, China
5 Xinqiao Hospital of Army Medical University, Chongqing, China
6 Xinqiao Hospital Army Medical University, Chongqing, Chongqing, China

Background:

Acute and chronic graft-versus-host disease (GVHD) represent distinct yet interconnected phases of alloimmune injury following allogeneic hematopoietic stem cell transplantation (allo-HSCT). While acute inflammation resolves in most patients, persistent immune activation in a subset of recipients drives progression to chronic GVHD (cGVHD), suggesting a critical transition window during which inflammatory programs become irreversibly established. Macrophages play a critical role in the pathogenesis of cGVHD and have emerged as therapeutic targets, exemplified by the recent clinical success of the CSF-1R–blocking antibody Axatilimab. However, a substantial proportion of patients fail to respond to CSF-1R–targeted therapy, indicating that pathogenic macrophage programs independent of CSF-1R signaling remain poorly understood. Defining the macrophage phenotypic changes that govern the transition from acute to chronic GVHD may uncover opportunities for early therapeutic intervention and improve prevention of cGVHD.

 Methods:

We integrated human GVHD bone marrow CITE-seq, human bronchiolitis obliterans syndrome (BOS) single-cell RNA sequencing, and murine single-cell RNA sequencing to identify macrophage programs associated with GVHD progression. Mechanistic studies were performed using IFN-β–stimulated macrophages, genetic silencing of Rsad2, and macrophage adoptive transfer models. The therapeutic efficacy of Panax notoginseng saponins (PNS), a mixture of triterpenoid glycosides extracted from Tienchi ginseng, in reprogramming pathogenic macrophages and preventing progression to cGVHD was validated in multiple murine GVHD models.

 Results:

Analysis of human GVHD bone marrow CITE-seq datasets revealed a conserved inflammatory myeloid remodeling program characterized by enhanced type I interferon responses. Kinetic analyses across independent MHC-mismatched murine GVHD models demonstrated the emergence of a senescent macrophage program during the transition from acute inflammation to chronic disease. Single-cell RNA sequencing of murine GVHD target tissues identified expansion of a CSF-1Rlow macrophage population characterized by persistent type I interferon signaling, inflammatory activation, DNA damage responses, and Cdkn1a-associated senescence signatures. Importantly, analysis of human pulmonary cGVHD (bronchiolitis obliterans syndrome, BOS) confirmed expansion of a conserved CSF1RlowRSAD2+CDKN1A+ macrophage population with elevated inflammatory senescence scores, validating the translational relevance of this pathogenic macrophage program. Mechanistically, IFN-β signaling drives macrophages to this pathogenic state through mitochondrial stress, cytosolic mitochondrial DNA accumulation, and activation of the Rsad2–cGAS–STING pathway, resulting in persistence of inflammatory cytokines and macrophage senescence. Adoptive transfer of IFN-β-primed macrophages accelerated cGVHD progression in mice, whereas Rsad2 knockdown reversed IFN-β-induced macrophage senescence and attenuated GVHD. Treatment with PNS interrupted this pathogenic transition by reprogramming IFN-driven senescent macrophages, suppressing Rsad2–cGAS–STING signaling, and reducing tissue inflammation and fibrosis without broad macrophage depletion.

 Conclusion:

These findings identify an IFN-β-driven senescent macrophage program as a critical regulator of the acute-to-chronic GVHD transition, linking persistent alloimmune inflammation to chronic tissue injury. Targeting this pathogenic macrophage state during the inflammatory transition window with PNS may provide a novel therapeutic strategy to prevent cGVHD before irreversible fibrosis is established.

Qingxiao Song, MD, PhD: No relevant conflicts of interest to declare.